Renaissance Technologies LLC Has $127,000 Position in Alpha Tau Medical Ltd. (NASDAQ:DRTS)

Renaissance Technologies LLC grew its stake in Alpha Tau Medical Ltd. (NASDAQ:DRTS) by 188.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,000 shares of the company’s stock after acquiring an additional 26,800 shares during the period. Renaissance Technologies LLC owned 0.06% of Alpha Tau Medical worth $127,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Levin Capital Strategies L.P. grew its holdings in Alpha Tau Medical by 2.3% during the 4th quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock worth $975,000 after acquiring an additional 7,189 shares during the period. 2.65% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Alpha Tau Medical in a research report on Tuesday, April 29th.

Alpha Tau Medical Stock Performance

Shares of DRTS opened at $2.59 on Wednesday. The stock has a 50 day simple moving average of $2.63 and a 200 day simple moving average of $2.86. Alpha Tau Medical Ltd. has a 52-week low of $1.75 and a 52-week high of $4.39. The firm has a market capitalization of $182.29 million, a PE ratio of -6.02 and a beta of 0.92.

Alpha Tau Medical (NASDAQ:DRTS) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13). Equities research analysts predict that Alpha Tau Medical Ltd. will post -0.45 EPS for the current fiscal year.

Alpha Tau Medical Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.